SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about revised presentation

10 Feb 2026 Evaluate

Aurobindo Pharma has informed that it attached the revised presentation that would be used in the investors / analysts call on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2025 to be held today, February 10, 2026 at 8.30 am. The revised presentation is also being uploaded to the following weblink of the Company. https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations.


The above information is a part of company’s filings submitted to BSE. 

Aurobindo Pharma Share Price

1384.45 -1.65 (-0.12%)
17-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1239.00
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2321.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×